• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

MBX Biosciences earns Buy rating at three investment firms

by October 8, 2024
written by October 8, 2024

Investing.com — Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company.

Analysts at Jefferies highlighted the potential of MBX’s lead program, MBX-2109, which is currently in Phase II trials for hypoparathyroidism.

They expressed confidence in the company’s scientific platform, particularly in the field of endocrine peptides, noting the possibility of significant improvements in treatment duration and the development of better medicines in established commercial areas.

MBX Biosciences’s platform is rooted in the extensive peptide and chemistry research of co-founder Dr. Richard DiMarchi, who brings over 20 years of academic experience and a track record of developing approved therapies. The firm underscored the strength of this scientific foundation, which has been augmented by years of R&D at Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO).

“The lead Phase II program in PTH has shown promising Phase I data with favorable pharmacokinetic (PK),” Jefferies analysts said.

“In 4 doses from 200-900ug MBX-2109 showed dose proportional increase in mean concentration and a 7-9-day half-life, supporting weekly dosing vs competitors that are all daily, with < 2-3 days half-life.”

Looking forward, Jefferies anticipates that MBX stock may benefit from upcoming industry catalysts. These include a strong commercial launch expected from competitor ASND in the first quarter of 2025, which could expand the market for hypoparathyroidism treatments.

Moreover, Phase III data from AstraZeneca PLC (LON:AZN) ADR (NASDAQ:AZN) expected in the first half of 2025 could further validate the platform and potentially increase confidence in MBX’s improved weekly dosing regimen.

Separately, Stifel and Guggenheim also started coverage on MBX with a Buy rating and optimistic price targets of $40 and $44, respectively.

Stifel’s endorsement is based on the strength of MBX’s precision endocrin peptides (PEPs) platform, which is engineered to improve pharmaceutical properties, including reducing injection frequency.

The firm anticipates multiple value-driving catalysts within the next 12 months that could demonstrate the platform’s capabilities.

Meanwhile, Guggenheim’s analysis points to MBX 2109, a once-weekly peptide targeting a market opportunity that the firm estimates to be over $7 billion.

The anticipation of positive Phase 2 results by the third quarter of 2025 is expected to significantly increase the company’s share value.

Furthermore, Guggenheim notes MBX 1416, a once-weekly GLP-1 antagonist, as a potential platform-confirming treatment with expected Phase 1 results in the fourth quarter of 2024. The company “is also in the early stages of developing monthly incretin coagonists for obesity,” analysts highlighted.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Fed unlikely to ‘skip’ cutting rates in November: Citi
next post
Brazilian airline Azul’s shares jump on debt deal with lessors

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • K+S cuts 2024 outlook, faces headwinds
    • Brazil stocks lower at close of trade; Bovespa down 1.09%

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy